Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

By Guangdi Li, E. De Clercq. Nature reviews. Drug discovery, 2020

1,583 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/cf9b2f09ba4586b7dc3c5af28a025eea778b50d0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

Citations in the corpus

SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat (2020, background): “Despite the lack of documented in vitro data supporting the antiviral efficacy on SARS-CoV-2, several antiviral chemotherapeutic agents have been registered for the clinical trials for the treatment of COVID-19 (Table 2) [72].”
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. (2020, neutral): “Age, median (IQR), y 49 (41-58) Mean (SD), 55.”
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease (2020, background): “With the ongoing pandemic of COVID-19, scientists and researchers around the globe are racing to find effective vaccines and antiviral drugs.(6) The viral polymerase inhibitor remdesivir holds the greatest promise and it is currently being evaluated in several clinical trials.”
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro (2020, background): “This Brief Report raises the possibility that ivermectin could be a useful antiviral to limit SARS-CoV-2, in similar fashion to those already reported (Dong et al., 2020; Elfiky, 2020; Gordon et al., 2020; Li and De Clercq, 2020; Wang et al., 2020) ; until one of these is proven to be beneficial in ”
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target (2020, background): “There are a number of pharmaceuticals already being tested [1, 2], but a better understanding of the underlying pathobiology is required.”
The Molecular Docking Study of Potential Drug Candidates Showing Anti-COVID-19 Activity by Exploring of Therapeutic Targets of SARS-CoV-2 (2020, background): “Several existing drugs have demonstrated potential effectiveness against COVID-19, including oseltamivir,[9] lopinavir,[10] ritonavir,[10] remdesivir,[11] favipiravir,[12] ribavirin,[12] chloroquine, and hydroxychloroquine.”
Predicting the growth and trend of COVID-19 pandemic using machine learning and cloud computing (2020, neutral): “World Health Organization (WHO) has declared the coronavirus outbreak a pandemic, while the virus continues to spread [3].”
C-reactive protein levels in the early stage of COVID-19 (2020, background): “Early monitoring of key indicators was an important basis to guide treatment strategies, and early assessment of the severity of patients' condition was of great value [10] .”
COVID-19: immunopathogenesis and Immunotherapeutics (2020, methodology): “Clinical trials involving interferons have already been initiated for testing the approved anti-hepatitis C virus combination therapy of a pegylated interferon plus ribavirin for patients with COVID-19 (ChiCTR2000029387).(64) Other immunomodulators, such as Pseudomonas aeruginosa and thymosin, may b”